Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031941 · ClinicalTrials.gov registry record · Phase 1
CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00031941: Completed Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
NCT00031941 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031941, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
Interventions
- DRUG lenalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00031941 record still lists
NCT00031941 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which lenalidomide is the first listed.
NCT00031941 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031941 about?
NCT00031941 is a clinical study titled "CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy". RATIONALE: CC-5013 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have solid tumors and/or lymphoma that did not respond to previous therapy.
What is the current status of trial NCT00031941?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-04. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00031941?
The interventions under investigation include: lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00031941?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia